The price increases in raw material are frightening. And with Ukraine likely to miss the wheat season, and no likelihood of an early end to sanctions against Russia, there’s no reason to think inflation will slow. Wheat prices up 100% over 12 months, coal 400%, gas 1000%… These are not normal. A lot of costs have been absorbed by producers but these are being passed on. I cannot see how this cost of living squeeze doesn’t become a collapse in consumer discretionary spending. All the money will be going on food and energy. And that’s before

@AAZMining is my biggest holding and I don't think everyone appreciates the opportunity it offers. Its unlike most miners as it produces metals rather than shares: gold and copper. Shares in issue were 112m in 2014, now 114m. Market cap £184m, SP 160p. Since 2018 #AAZ has paid dividends of 19.5c, with 9c paid in 2020 and a special dividend expected to be declared very soon. They have no debt and at year end near $40m of cash. 2020 was a year when everything went wrong - pandemic followed by war - and they missed production targets as key staff

Well, its been a long wait at #AAZ but no matter how you look at it, the new mines, one of which produces 120k oz annually and has reserves of 8m oz must surely make the company worth at least 2.5 times what it was worth 6 months ago, when it was producing 80k oz of course it will take time to get everything productive, but the RNS today shows a huge increase in resources and the prospect of a real acceleration at Ordubad, which is a huge, 45m oz resource that has been stuck in an enclave and hard to progress. Upshot is, current SP

#DDDD is a big holding for me that I built between March and, well, last Friday. A lot of people think of it as a pharma company with the attendant risks of drug development. I don’t think that’s right. My understanding is that @4dpharmaplc have a huge amount of data concerning the make up of gut bacteria in people with various conditions and “healthy” people. From analysis they can see what bacteria are dominant and which are missing among those with afflictions. But crunching the data is key, as is the philosophy of using